Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfò L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL

Open source

DOI: 10.1182/bloodadvances.2025017489
Published: 2026 Apr 14
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025017489,
  title = {Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.},
  author = {Patel K and Vose JM and Nasta SD and Brown JR and Maddocks KJ and Woyach JA and Shah NN and Fakhri B and Tessoulin B and Ma S and Jagadeesh D and Lech-Maranda E and Coombs CC and Patel MR and Rhodes JM and Ujjani C and Hoffmann MS and Cheah CY and Munir T and Lewis D and Scarfò L and Eyre TA and Alencar A and Cohen JB and Zelenetz AD and Tsai DE and Li M and Bian Y and Abada P and Balbas M and Zinzani PL},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025017489},
  url = {https://doi.org/10.1182/bloodadvances.2025017489}
}

RIS

TY  - JOUR
TI  - Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
AU  - Patel K
AU  - Vose JM
AU  - Nasta SD
AU  - Brown JR
AU  - Maddocks KJ
AU  - Woyach JA
AU  - Shah NN
AU  - Fakhri B
AU  - Tessoulin B
AU  - Ma S
AU  - Jagadeesh D
AU  - Lech-Maranda E
AU  - Coombs CC
AU  - Patel MR
AU  - Rhodes JM
AU  - Ujjani C
AU  - Hoffmann MS
AU  - Cheah CY
AU  - Munir T
AU  - Lewis D
AU  - Scarfò L
AU  - Eyre TA
AU  - Alencar A
AU  - Cohen JB
AU  - Zelenetz AD
AU  - Tsai DE
AU  - Li M
AU  - Bian Y
AU  - Abada P
AU  - Balbas M
AU  - Zinzani PL
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025017489
UR  - https://doi.org/10.1182/bloodadvances.2025017489
ER  -

APA

K, P., JM, V., SD, N., JR, B., KJ, M., JA, W., NN, S., B, F., B, T., S, M., D, J., E, L., CC, C., MR, P., JM, R., C, U., MS, H., CY, C., T, M., D, L., L, S., TA, E., A, A., JB, C., AD, Z., DE, T., M, L., Y, B., P, A., M, B., & PL, Z. (2026). Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.. Blood advances. https://doi.org/10.1182/bloodadvances.2025017489

Source records

pubmed · retrieved 2026-09-26T21:23:56.551Z